Shanghai Sonyt Biotechnology Co., Ltd. is one of the leading manufacturers and suppliers of cas 254110-79-7 cef27,epstein-barrvirusbrlf-1lytic(148-156) in China, also supports custom service. Welcome to wholesale bulk high quality cas 254110-79-7 cef27,epstein-barrvirusbrlf-1lytic(148-156) from our factory. Contact us for more details.
| Description | EBV lytic immediate-early BRLF-1 residues 148–156, an HLA-restricted CD8+ epitope; used for EBV reactivation monitoring and ELISPOT. |
Product Basic Information Table
| Product Standard English Name | Product Abbreviation / Alias | Function Tags (comma-separated) | Core Structure | Molecular Formula | Exact Mass (Da) | Average MW (Da) | Salt Form | Length (aa) |
| CEF27, EBV BRLF-1 lytic (148-156) Peptide (RVRAYTYSK, HLA-A*03:01-restricted, CAS 254110-79-7) | CEF27; EBV BRLF1/Rta 148-156; RVRAYTYSK; EBV lytic-phase CD8+ T-cell epitope; CEF peptide pool component #27; R&D PP50756; Molnova M29966; CAS 254110-79-7 | EBV epitope,CEF peptide pool,CD8+ T-cell epitope,HLA-A*03:01,lytic phase,tetramer,viral immunity monitoring,T-cell immune monitoring | Linear 9-mer, H-Arg-Val-Arg-Ala-Tyr-Thr-Tyr-Ser-Lys-OH (RVRAYTYSK); derived from Epstein-Barr virus immediate-early lytic transactivator BRLF1 (Rta, UniProt P03209, EBV B95-8; note: NOT P03213, which is the BBRF1 portal protein) residues 148-156; component #27 of the CEF (CMV/EBV/Influenza) CD8+ T-cell epitope peptide pool, HLA-A*03:01-restricted CD8+ T-cell epitope; contains 2x Tyr (positions 5, 7) - protect from light; no Cys/Met/Trp; 2x Arg gives a basic character | C51H82N16O14 | 1142.62 | 1143.31 | Not specified (synthetic peptide is routinely supplied as TFA salt, final COA prevails; free peptide formula C51H82N16O14, MW 1142.62/1143.31; CAS 254110-79-7 consistently assigned to this free peptide RVRAYTYSK across 6 independent sources) | 9 |
Physicochemical Solubility & Storage Parameters
| Product Code | Appearance | Long-term Storage | Short-term Storage | Solution Stability | Solid Powder Stability |
| PEP-CEF27-01 | White to off-white powder (standard for synthetic peptides) | Store at -20°C, sealed, light-protected and dry, >= 2 years (per supplier); contains 2x Tyr - keep light-protected (amber vial / foil) against photo-oxidation; keep moisture-proof; aliquot single-use portions to avoid repeated freeze-thaw | Store at 2-8°C, sealed, light-protected and dry, for approx. 2 weeks; after opening keep in a desiccator and weigh rapidly; working aliquots light-protected at -20°C; ship on ice packs | Hydrophobic 9-mer with limited water solubility: prepare a 5-10 mg/mL DMSO stock, then dilute with PBS/culture medium to working concentration (commonly 1-10 ug/mL, approx. 1-10 uM); contains 2x Tyr - keep light-protected; no Cys/Met/Trp - no anti-oxidation requirement; filter-sterilize through 0.22 um; allow to reach room temperature before opening; store DMSO aliquots light-protected at -20°C and prepare working solutions fresh | solid stable >= 2 years at -20°C, sealed, light-protected and dry (supplier data); contains 2x Tyr - protect from light; no Cys/Met/Trp - no reducing agent or inert gas needed; keep dry and light-protected after opening |
Functional Description
| Product Code | Frontend Short Summary | Detailed Biological Function Description | Applicable Research Areas (comma-separated) | Targets / Receptors |
| PEP-CEF27-01 | CEF27 (EBV BRLF1/Rta 148-156, RVRAYTYSK, CAS 254110-79-7), the HLA-A*03:01-restricted EBV lytic-phase CD8+ T-cell epitope, purity >98% (HPLC), used for EBV-specific T-cell immune monitoring, CEF pool stimulation and tetramer preparation. | RVRAYTYSK, a nonapeptide at residues 148-156 of the Epstein-Barr virus (EBV B95-8) immediate-early lytic transactivator BRLF1 (Replication and transcription activator, Rta; UniProt P03209, 605 aa - note the correct accession is P03209, whereas P03213 is the BBRF1 portal protein), is component #27 of the CEF (CMV/EBV/Influenza) CD8+ T-cell epitope peptide pool and is confirmed by R&D Systems (PP50756) and Molnova (M29966) as an HLA-A*03:01-restricted epitope (note: NOT HLA-A*02:01; the confusable candidate YVLDHLIVV belongs to Rta 28-37, i.e. CEF14 DYCNVLNKEF, and is unrelated to this product). CAS 254110-79-7 is consistently assigned to this peptide across 6 independent supplier/MSDS sources; Molnova lists purity >98% (HPLC) and >= 2 years stability at -20°C. Widely used for: (1) in vitro stimulation and expansion of EBV-specific CD8+ T cells (as a CEF pool component); (2) pMHC-I (HLA-A*03:01) tetramer assembly and flow-cytometric detection; (3) immune monitoring of EBV-specific T cells in healthy carriers and transplant patients; (4) studies of EBV lytic-phase cellular immunity and viral reactivation. Note the distinction from previously handled CEF14 (Rta 28-37, DYCNVLNKEF, HLA-A*24:02) and EBV-BRLF1-134-142 (ATIGTAMYK) - different segments of BRLF1 with different HLA restrictions. | EBV-specific T-cell monitoring,CEF peptide pool stimulation,CD8+ T-cell epitope,HLA-A*03:01 tetramer,viral immunity research,post-transplant EBV reactivation monitoring,lytic-phase immune response | HLA-A*03:01 (MHC-I) presenting the EBV BRLF1/Rta 148-156 epitope to epitope-specific CD8+ T cells |
Hot Tags: cas 254110-79-7 cef27,epstein-barrvirusbrlf-1lytic(148-156), China cas 254110-79-7 cef27,epstein-barrvirusbrlf-1lytic(148-156) manufacturers, suppliers, factory, cateninpeptide, 124454-83-7, 125366-42-9, 265669-37-2, CAS 199727 68 9, CEF4
